Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer.

Trial Profile

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Docetaxel; Imatinib
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Aug 2009 Additional lead trial centre and sponsor (Novartis), actual number of patients (28) added as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 28 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top